Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
View/ Open
Date
2025-01Author
Iturbe Rey, Santiago
Maccali, Claudia
Arrese, Marco
Aspichueta Celaá, Patricia
Oliveira, Claudia P.
Castro, Rui E.
Lapitz Dambolenea, Ainhoa
Izquierdo Sánchez, Laura
Bañales Asurmendi, Jesús María
Rodrigues, Pedro M.
Metadata
Show full item record
Atherosclerosis 400 : (2025) // Article ID 119053
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver lesions, ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), that may further progress to cirrhosis. MASLD is estimated to affect more than one third of the general population and it represents a risk factor for end-stage liver failure and liver cancer, substantially contributing to liver-related morbidity and mortality. Although the pathogenesis of MASLD is incompletely understood, it is known to consist of a multifactorial process influenced by extrinsic and intrinsic factors such as metabolic, environmental and demographic features, gut microbiota and genetics. Dysregulation of both extracellular and intracellular lipid composition is known to promote the generation of toxic lipid species, thereby triggering lipotoxicity and cellular stress. These events ultimately lead to the activation of distinct cell death pathways, resulting in inflammation, fibrogenesis and, eventually, carcinogenesis. In this manuscript, we provide a comprehensive review of the role of lipotoxicity during MASLD pathogenesis, discussing the most relevant lipid species and related molecular mechanisms, summarizing the cell type-specific effects and highlighting the most promising putative therapeutic strategies for modulating lipotoxicity and lipid metabolism in MASLD.